Oxaliplatin, Irinotecan, and Capecitabine in Treating Patients With Advanced or Metastatic Colorectal Cancer That Cannot Be Removed By Surgery

Sponsor
Swiss Cancer Institute
Study ID
NCT00217711
Phase
PHASE1/PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

  • Capecitabine — DRUG
    capecitabine
  • irinotecan hydrochloride — DRUG
    irinotecan hydrochloride
  • oxaliplatin — DRUG
    oxaliplatin

Study Details

RATIONALE: Drugs used in chemotherapy, such as oxaliplatin, irinotecan, and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of capecitabine when given together with oxaliplatin and irinotecan and to see how well they work in treating patients with advanced or metastatic colorectal cancer that cannot be removed by surgery.

Key Dates

Start date
May 31, 2005
Status verified
Jun 2012
Primary completion
Aug 31, 2007
Completion
Oct 31, 2011

Study Design

Enrollment
23 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Active Comparator: Arm A
    Oxaliplatin, Irinotecan, and Capecitabine

Primary Outcome Measure

capecitabine + oxaliplatin + irinotecan dose finding [ Time Frame: 30 days ]

Related Studies